NCT06427941 - A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric CancerExtragonadal Yolk Sac TumorsGlypican-3 (GPC3)-Positive Squamous Non-small Cell Lung CancerMetastatic Solid Tumor

Interventions

DRUG

BGB-B2033

Administered by intravenous infusion

DRUG

Tislelizumab

Administered by intravenous infusion

Trial Locations (15)

1023

RECRUITING

Auckland City Hospital, Auckland

13496

RECRUITING

Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi

150000

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

230000

RECRUITING

Anhui Provincial Hospital, Hefei

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

330038

RECRUITING

The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch, Nanchang

350025

RECRUITING

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

410013

RECRUITING

Hunan Cancer Hospital, Changsha

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

510515

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

37203-1503

RECRUITING

Scri Oncology Partners, Nashville

98374-2118

RECRUITING

Upmc Hillman Cancer Center, Puyallup

06351

RECRUITING

Samsung Medical Center, GangnamGu

03722

RECRUITING

Severance Hospital Yonsei University Health System, SeodaemunGu